5 Key Takeaways
-
1
Retinal therapy development involves regulatory, clinical trial, manufacturing, reimbursement, and treatment-delivery challenges beyond demonstrating efficacy.
-
2
Panelists said AI-based imaging analysis and real-world evidence could support patient recruitment, endpoint selection, and clinical trial design.
-
3
For therapies targeting severe retinal degeneration, panelists called for outcome measures that capture functional improvements meaningful to patients.
-
4
Cell and gene therapy developers must address manufacturing capacity, product storage and preparation, surgical training, and patient awareness.
-
5
Panelists said reimbursement planning should begin before regulatory approval, and treatment delivery may require support beyond the procedure itself.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







